Lemborexant in insomnia disorder: a profile of its use

Compliance with ethical standards

Funding: The preparation of this review was not supported by any external funding.

Conflict of interest: H. A. Blair is an employee of Adis International Ltd./Springer Nature, is responsible for the article content, and declares no conflicts of interest.

Additional information about this Adis Drug Review can be found here.

Abstract Lemborexant (Dayvigo^™), a dual orexin receptor antagonist, is an effective and well-tolerated treatment option for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. In phase 3 clinical trials, oral lemborexant 5 or 10 mg once nightly significantly reduced sleep onset latency (SOL) and wake-after-sleep onset (WASO), and improved sleep efficiency (SE). Lemborexant was also associated with reductions in patient-reported fatigue and insomnia severity, and was well tolerated through 12 months of treatment. In special safety studies, lemborexant did not increase the auditory awakening threshold or cause next-day postural instability, and was not associated with rebound insomnia, withdrawal symptoms, or clinically meaningful impairment of next-day memory or driving performance.

© Springer Nature Switzerland AG 2020